Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Piper Sandler Downgrades CymaBay Therapeutics to Neutral, Lowers Price Target to $32.5

Author: Benzinga Newsdesk | February 14, 2024 07:11am
Piper Sandler analyst Yasmeen Rahimi downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Overweight to Neutral and lowers the price target from $33 to $32.5.

Posted In: CBAY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist